Daveen Chopra - 15 Mar 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, TMTT
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
15 Mar 2023
Net transactions value
-$142,760
Form type
4
Filing time
15 Mar 2023, 17:28:08 UTC
Previous filing
15 Feb 2023
Next filing
04 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $200,802 +4,435 +23% $45.28 23,346 15 Mar 2023 Direct F1
transaction EW Common Stock Sale $343,563 -4,435 -19% $77.47 18,911 15 Mar 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -4,435 -100% $0.000000* 0 15 Mar 2023 Common Stock 4,435 $45.28 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $77.20 to $77.67 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.